IRT5 Probiotics Changes Immune Modulatory Protein Expression in the Extraorbital Lacrimal Glands of an Autoimmune Dry Eye Mouse Model

Se Hyun Choi,1,2 Jae Won Oh,3,4 Jin Suk Ryu,1 Hye Min Kim,3 Sin-Hyeog Im,5,6 Kwang Pyo Kim,3,4 and Mee Kum Kim1,7

1Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul National University Hospital Biomedical Research Institute, Seoul, Republic of Korea
2Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Republic of Korea
3Department of Applied Chemistry, Institute of Natural Science, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University, Yongin, Republic of Korea
4Department of Biomedical Science and Technology, Kyung Hee Medical Science Research Institute, Kyung Hee University, Seoul, Republic of Korea
5Division of Integrative Biosciences and Biotechnology, Department of Life Science, Pohang University of Science and Technology, Pohang, Republic of Korea
6Academy of Immunology and Microbiology, Institute for Basic Science, Pohang, Republic of Korea
7Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea

Correspondence: Mee Kum Kim, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Republic of Korea; kmk9@snu.ac.kr.

Kwang Pyo Kim, College of Applied Science, Kyung Hee University, Yonginro, Yongin 12224, Republic of Korea; kimkp@khu.ac.kr.

SHC and JWO contributed equally to the work presented here and should therefore be regarded as equivalent authors.

Received: October 8, 2019
Accepted: January 16, 2020
Published: March 30, 2020

Citation: Choi SH, Oh JW, Ryu JS, et al. IRT5 probiotics changes immune modulatory protein expression in the extraorbital lacrimal glands of an autoimmune dry eye mouse model. Invest Ophthalmol Vis Sci. 2020;61(3):42. https://doi.org/10.1167/iovs.61.3.42

PURPOSE. While the association between the gut microbiome and the immune system has been studied in autoimmune disorders, little is known about ocular disease. Previously we reported that IRT5, a mixture of five probiotic strains, could suppress autoimmune dry eye. In this study, we investigated the mechanism by which IRT5 performs its immunomodulatory function in a mouse model of autoimmune dry eye.

METHODS. NOD.B10.H2b mice were used as an autoimmune dry eye model. Either IRT5 or PBS was gavaged orally for 3 weeks, with or without 5 days of antibiotic pretreatment. The effects on clinical features, extraorbital lacrimal gland and spleen proteins, and fecal microbiota were analyzed.

RESULTS. The ocular staining score was lower, and tear secretion was higher, in the IRT5-treated groups than in the PBS-treated groups. After IRT5 treatment, the downregulated lacrimal gland proteins were enriched in the biological processes of defense response and immune system process. The relative abundances of 33 operational taxonomic units were higher, and 53 were lower, in the feces of the IRT5-treated groups than in those of the PBS-treated groups. IRT5 administration without antibiotic pretreatment also showed immunomodulatory functions with increases in the Lactobacillus helveticus group and Lactobacillus hamsteri. Additional proteomic assays revealed a decrease of proteins related to antigen-presenting processes in the CD11b+ and CD11c+ cells of spleen in the IRT5-treated groups.

CONCLUSIONS. Changes in the gut microbiome after IRT5 treatment improved clinical manifestations in the autoimmune dry eye model via the downregulation of antigen-presenting processes in immune networks.

Keywords: IRT5, probiotics, autoimmune dry eye, gut microbiome, proteomics, antigen presentation, cornea

The human microbiome project and advancement in metagenomic analysis have revealed that the gut microbiome modulates human diseases by affecting the metabolism and both innate and adaptive immunity.1-5 Dry eye disease associated with Sjögren syndrome is a well-known autoimmune disease.6 Many autoimmune disease or metabolic syndromes, including Sjögren syndrome, may be affected by aberrant interaction between the immune system and gut microbiome.3-5 For example, a dysbiotic intestinal microbiome has been shown to affect autoimmune uveitis and dry eye.8-13 Whether probiotics exert beneficial effects on inflammatory or metabolic diseases has long been debated.14,15 Recent meta-analytic human studies reported favorable microbiome effects on clinical manifestations in diabetes, necrotizing enterocolitis, inflammatory bowel disease, and...
IRT5 Changes the Lacrimal Gland Protein Expression

METHODS

Animals

Twelve-week-old male NOD.B10.H2b mice (from The Jackson Laboratory, Bar Harbor, ME, USA) were used as the autoimmune dry eye model (n = 35). Due to the poor breeding properties of NOD.B10.H2b mice, we conducted four repeated experiments focused on different analysis. The number of mice used in each experiment is as follows.

- **Experiment 1:** Five mice in the PBS group and five mice in the IRT5 group were used for the clinical evaluation and proteomic analysis of the extraorbital lacrimal glands after antibiotic pretreatment.
- **Experiment 2:** Four mice in the PBS group and five mice in the IRT5 group were used for the clinical evaluation and proteomic analysis of the lymph nodes and spleen after antibiotic pretreatment.
- **Experiment 3:** Three mice in the PBS group and four mice in the IRT5 group were used for clinical evaluation and gut microbiome analysis after antibiotic pretreatment.
- **Experiment 4:** Four mice in the PBS group and five mice in the IRT5 group were used for clinical evaluation and gut microbiome analysis without antibiotic pretreatment.

Mice were bred in a specific pathogen-free facility at the Biomedical Research Institute of Seoul National University Hospital (Seoul, Korea) and maintained at 22–24°C, relative humidity 55% ± 5%, with free access to food and water. All mice were managed in accordance with the Association for Research in Vision and Ophthalmology guidelines for the Use of Animals in Ophthalmic and Vision Research. The study was approved by the Institutional Animal Care and Use Committee of the Seoul National University Biomedical Research Institute (IAUCUC No. 17-0093-C1A0 and 18-0129-S1A0).

Antibiotics Pretreatment and IRT5 Treatment

Of the 35 mice, antibiotic pretreatment was performed on 26 and the remaining 9 were not pretreated.

In the pretreatment group, a cocktail of 1 g l−1 ampicillin, 500 mg l−1 vancomycin, and 1 g l−1 metronidazole (all from Sigma-Aldrich, St. Louis, MO, USA) was administered in drinking water for 5 days before the start of the treatment. The IRT5 probiotic powder containing 2 × 10^8 CFU g−1 of five strains (L. casei, L. acidophilus, L. reuteri, B. bifidum, and S. thermophiles) was kindly provided by Young-Tae Ahn (Korea Yakult Co., Giheung, Korea). Either PBS alone (n = 12) or 1 × 10^8 IRT5 probiotics (n = 14) in 300 μL PBS was gavaged orally once a day for 3 weeks.

In the non-pretreatment group, either PBS (n = 4) or IRT5 probiotics (n = 5) was gavaged orally once a day for 3 weeks.

Clinical Evaluation

Phenol red–impregnated cotton threads (FCI Ophthalmics, Pembroke, MA, USA) were inserted for 60 seconds into the lateral canthus of mice under anesthesia (anesthetized using a mixture of zotelin and xylazine at a ratio of 1:3). The amount of tears secreted was determined by measuring the wet length of the wet thread in millimeters. After instilling one drop of 3% Lissamine Green B (Sigma-Aldrich) to the lower lateral conjunctival sac, corneal epithelial defect was scored in a blinded manner as follows: 0 if no punctuate staining was observed, 1 if less than one-third of the cornea was staining, 2 if two-thirds or less was stained, and 3 if more than two-thirds of the cornea was stained.

Proteomics Sample Preparation

Lacrimal gland samples from NOD mice treated with PBS (control, n = 5) or IRT5 (n = 5) after antibiotic pretreatment were individually pulverized using a Cryoprep device (CP02, Covaris, Inc., Woburn, MA, USA). The pulverized tissue powder was sonicated in lysis buffer (4% SDS, 0.1M Tris-HCl pH 7.6, 1× Halt protease inhibitor cocktail [Hoffmann-La Roche AG, Basel, Switzerland] in 10 mL). The homogenate was centrifuged at 16,000 × g and 20°C for 10 minutes, and the supernatant was collected for protein digestion. The protein concentration was measured using a bicinchoninic acid (BCA) protein assay (BCA Protein Assay Kit; Thermo Fisher Scientific, San Jose, CA, USA). One hundred micrograms of proteins from each tissue was digested using a filter-aided sample preparation (FASP) method following published instructions. The peptides were labeled with TMT 10-plex reagent (Thermo Fisher, Waltham, MA, USA), according to the manufacturer's protocol. The five peptide samples from the PBS-treated mice were labeled as 126, 127N, 127C, 128N, and 128C, and the five from the IRT5 mice were labeled as 129N, 129C, 130N, 130C, and 131. The labeled peptides were pooled and fractionated into 12 fractions using high-pH reversed-phase fractionation. The peptides from the 12 fractions were dried and desalted using a C18 spin column (Thermo Fisher).

The spleens of the NOD mice treated with PBS (control, n = 4) or IRT5 (n = 5) after antibiotics pretreatment were cut in half. The CD11b+ cells were sorted in one half and the CD11c+ cells were sorted in the other half. The cervical and mesenteric lymph nodes of each mouse were pooled and only CD3+ cells were obtained.
Fecal Microbiota 16S Ribosomal RNA Analysis

Fecal pellets were collected directly from the anus of each mouse by holding the mouse in one hand while allowing it to defecate into a sterile tube. The collected feces were immediately stored at –80°C. For the analysis of bacteria in the feces, PCR amplification was performed using extracted DNA and the bacterial PCR primers 341F (5′-TCTGTCGCGACTCAG-3′; underlined sequence indicates the target region primer) and 805R (5′-GTCTCGTGGCAGCGTCAG-3′) targeting the V3 to V4 regions of the 16S ribosomal RNA (rRNA) gene. The reaction conditions were as follows: 3 minutes of initial denaturation at 95°C, 25 cycles of 30-second denaturation at 95°C, 30-second primer annealing at 55°C, 30-second elongation at 72°C, and a final extension at 72°C for 5 minutes. Secondary amplification was performed using the i5 forward primer (5′-AATGATACGGCGACACATCTATCGGAT-XXXXXXGTTCGGGCAAGGTCAG-3′; X indicates the barcode region) and i7 reverse primer (5′-CAAGCAGAAGACGGCATACGAGAT-XXXXXXGTTCGGGCTTCGAG-3′) for attaching the Illumina NexTera barcode. The secondary amplification conditions were identical to those of the first amplification except that the number of amplification cycles was set to eight. The amplified products were confirmed using gel electrophoresis on 1.0% agarose gel and visualized using a Gel Doc system (BioRad, Hercules, CA, USA). CleanPCR (CleanNA) was used for purifying the amplified products. The same concentrations of purified product were pooled and short fragments were removed using CleanPCR (nontarget product). The product size and quality were evaluated on a Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA) using a DNA 7500 chip. Mixed amplicons were pooled and sequenced using an Illumina MiSeq Sequencing system (Illumina, Inc., San Diego, CA, USA) at ChunLab, Inc. (Seoul, Korea) according to the manufacturer’s instruction. Raw read processing began with quality checking and filtering of low-quality (<Q25) reads by Trimmomatic 0.32.31 Paired-end sequence data were merged using PANDAseq after passing quality filtering to generate additional Operational Taxonomic Unit (OTUs).35 OTUs with single reads were omitted from further analysis. We clustered the sequences and grouped them as OTUs.35 OTUs with nonspecific amplicons that do not encode 16S rRNA.33 The EzBioCloud database was searched for taxonomic assignment, and the nonchimeric 16S rRNA database from EzBioCloud was used.32 Reads that were not identified to the species level (<97% similarity) in the EzBioCloud database were compiled and UCLUST was used for de novo clustering to generate additional Operational Taxonomic Unit (OTUs).35 OTUs with single reads were omitted from further analysis.

Sequence Analysis

We clustered the sequences and grouped them as OTUs. BIOPLUG software (ChunLab) was used to summarize the OTU data and to calculate the microbial alpha and beta diversity, and a linear discriminant analysis (LDA) of the
**FIGURE 1.** Clinical manifestations in the mouse cornea. (A) Representative images of mouse cornea before and after the PBS and IRT5 treatment. Lissamine Green B was used to visualize the wounded areas of the mouse corneas. (B) The ocular staining score of the IRT5-treated group ($n = 14, 28$ eyes) was significantly lower than that of the PBS-treated group ($n = 12, 24$ eyes). (C) Tear secretion in the IRT5-treated group was significantly higher than that of the PBS-treated group. ***$P < 0.0001$ (data presented as box-and-whisker plot with median).

**IRT5 Probiotics Change Immunomodulatory or Ionic Transport-Related Protein Expression in the Extraorbital Glands**

Quantitative proteome analysis identified a total of 5379 proteins in the extraorbital glands with a FDR of less than 1% at peptide spectrum match levels (Supplementary Table S1). Among the identified proteins, 202 proteins were selected as DEPs (changes in expression $\geq 1.15$-fold of the reporter ion intensity using Student’s $t$-test; $P < 0.05$) (Fig. 2A, Supplementary Table S2). To gain insight into the functional roles of DEPs in the effects of ITR5 treatment, a comparison of the gene ontology (GO) of the biological processes (BPs) of the DEPs was performed. A heatmap of GOBP enrichment analysis showed significantly represented GOBP terms ($P < 0.05$) for DEPs in the IRT5-treated group compared with the PBS-treated group. Proteins related to immune system process and defense response were significantly downregulated and proteins associated with actin cytoskeleton organization, cell adhesion, and proteolysis were significantly upregulated (Fig. 2B). To understand the changes in the maps of the cellular networks in the lacrimal glands after IRT5 treatment, we constructed network models using the DEPs from the lacrimal glands. We grouped the network proteins into eight modules, including protein transport, exocytosis/endocytosis, lipid metabolic process, proteolysis, immune system process, cell cycle, mitochondria electron transfer, and cell adhesion based on the GO biological processes and KEGG pathways (Fig. 3).

Among these DEPs, Table 1 lists the proteins that exhibited high betweenness centrality (the top 10% of protein-protein interactions). The proteins that possessed the high betweenness centrality ($>0.5$, the top 7% of protein-protein interactions in decreasing order) were mitochondrial cytochrome c oxidase subunit 7C (Cox7c), zyxin (Zyx), charged multivesicular body protein 4c (Chmp4c), peroxisome assembly factor 2 (Pex2), paraplegin (Spg7), ubiquitin-conjugating enzyme E2 D3 (Ubc2d3), sedoheptulokinase (Shpk), receptor-type tyrosine-protein phosphatase C (PTPRC), and Golgi SNAP receptor complex member 2 (Gsrc).
IRT5 Changes the Lacrimal Gland Protein Expression

**FIGURE 2.** Volcano plot of total protein identified in the extraorbital lacrimal glands after the PBS (n = 5) and IRT5 (n = 5) treatment and gene ontology analysis of 202 DEPs. (A) Volcano plot displaying all proteins that were identified by at least two unique peptides. (B) The heat map of the GOBP enrichment analysis showed significantly represented GOBP terms (P < 0.05) in the IRT5-treated group (only biological processes that satisfy P < 0.05 were included). Proteins associated with immune system process were significantly downregulated and proteins related to actin cytoskeleton organization, cell adhesion, and proteolysis were upregulated.

**FIGURE 3.** Protein network showing the proteomic changes after the PBS (n = 5) and IRT5 (n = 5) treatment. Protein interaction was schematized as a network using STRING and the Cytoscape program.
IRT5 Changes the Lacrimal Gland Protein Expression

**Table 1.** Differentially Expressed Proteins that Have High Betweenness Centrality

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Protein Name</th>
<th>Betweenness Centrality</th>
<th>Fold Change</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cox7c</td>
<td>Cytochrome c oxidase subunit 7C, mitochondrial</td>
<td>1.000</td>
<td>0.870</td>
<td>0.001</td>
</tr>
<tr>
<td>Zyx</td>
<td>Zyxin</td>
<td>1.000</td>
<td>1.269</td>
<td>0.022</td>
</tr>
<tr>
<td>Chmp4c</td>
<td>Charged multivesicular body protein 4c</td>
<td>0.667</td>
<td>1.261</td>
<td>0.012</td>
</tr>
<tr>
<td>Pex6</td>
<td>Peroxisome assembly factor 2</td>
<td>0.667</td>
<td>1.229</td>
<td>0.016</td>
</tr>
<tr>
<td>Spg7</td>
<td>Paraplegin</td>
<td>0.667</td>
<td>1.544</td>
<td>0.049</td>
</tr>
<tr>
<td>Ube2d3</td>
<td>Ubiquitin-conjugating enzyme E2 D3</td>
<td>0.667</td>
<td>0.813</td>
<td>0.045</td>
</tr>
<tr>
<td>Shpk</td>
<td>Sedoheptulokinase</td>
<td>0.650</td>
<td>1.197</td>
<td>0.041</td>
</tr>
<tr>
<td>Ptpcr</td>
<td>Receptor-type tyrosine-protein phosphatase C</td>
<td>0.521</td>
<td>0.757</td>
<td>0.000</td>
</tr>
<tr>
<td>H2-K1</td>
<td>H-2 class I histocompatibility antigen, K-B alpha chain</td>
<td>0.215</td>
<td>0.772</td>
<td>0.000</td>
</tr>
<tr>
<td>Icam1</td>
<td>Intercellular adhesion molecule 1</td>
<td>0.171</td>
<td>0.835</td>
<td>0.025</td>
</tr>
<tr>
<td>Agps</td>
<td>Alkyldihydroxyacetonephosphate synthase, peroxisomal</td>
<td>0.150</td>
<td>0.858</td>
<td>0.009</td>
</tr>
<tr>
<td>D2hgdh</td>
<td>D-2-hydroxyglutarate dehydrogenase, mitochondrial</td>
<td>0.150</td>
<td>0.845</td>
<td>0.047</td>
</tr>
</tbody>
</table>

* > 0.05 P value, >1.2- or <0.83-fold change, >0.1 betweenness centrality cutoff was applied.

**Table 2.** DEPs Related to Dry Eye, Sjögren Syndrome, or Autoimmune Disease Through Immune Modulation

<table>
<thead>
<tr>
<th>Biological Process</th>
<th>Protein Name</th>
<th>Gene Name</th>
<th>Fold Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune response</td>
<td>Receptor-type tyrosine-protein phosphatase C</td>
<td>Ptpcr</td>
<td>0.757</td>
</tr>
<tr>
<td></td>
<td>High mobility group protein B2</td>
<td>Hmgb2</td>
<td>0.774</td>
</tr>
<tr>
<td></td>
<td>Proteasome subunit beta type-8</td>
<td>Psmb8</td>
<td>0.805</td>
</tr>
<tr>
<td></td>
<td>H-2 class II histocompatibility antigen, A-B alpha chain</td>
<td>H2-Aa</td>
<td>0.666</td>
</tr>
<tr>
<td></td>
<td>H-2 class I histocompatibility antigen, K-B alpha chain</td>
<td>H2-K1</td>
<td>0.772</td>
</tr>
<tr>
<td></td>
<td>Proteasome activator complex subunit 1</td>
<td>Psmb9</td>
<td>0.815</td>
</tr>
<tr>
<td></td>
<td>Antigen peptide transporter 1</td>
<td>Tap1</td>
<td>0.765</td>
</tr>
<tr>
<td></td>
<td>Antigen peptide transporter 2</td>
<td>Tap2</td>
<td>0.815</td>
</tr>
<tr>
<td></td>
<td>Proteasome subunit beta type 9</td>
<td>Psmb9</td>
<td>0.770</td>
</tr>
<tr>
<td>Cell adhesion</td>
<td>Intercellular adhesion molecule 1</td>
<td>Icam1</td>
<td>0.835</td>
</tr>
</tbody>
</table>

* > 0.05 P value, >1.2- or <0.83-fold change was applied for enriching the DEPs.

Among these, Shpk and Ptpcr are enriched in immune system process with high betweenness centrality in this network model. Additionally, Pex6, Gosl2, protein transport protein Sec16B (Sec16b), antigen peptide transporter 2 (TAP2), and antigen peptide transporter 1 (TAP1) are grouped in protein transport forming a close network with immune system process within the protein-protein network model (Fig. 3).

Among the DEPs, proteins that have been reported to be associated with dry eye syndrome, Sjögren syndrome, or autoimmune disease through modulating immunity are shown in Table 2. Ptpcr, which plays an important role in T-cell activation and B-cell proliferation in the MRL/MpJ-lpr mouse model, was downregulated and clustered in immune system process after IRT5 treatment. High mobility group protein B2 (Hmgb2), which is reportedly highly expressed in Sjögren syndrome, was downregulated after IRT5 treatment. These proteins are mostly involved in immune system process and may be significant in restoring the functioning of the lacrimal gland after IRT5 treatment. Although its relationship with dry eye is not clear, Cox 7c, one of the terminal oxidases of mitochondrial electron transfer, was also downregulated after IRT5 treatment.

**Treatment with IRT5 Probiotics Changes Gut Microbiome Composition**

To promote the survival of IRT5 probiotics in the gut, oral antibiotics were applied for 5 days prior to treatment in 26 mice in both the PBS (n = 12) and IRT5 (n = 14) groups. Of the 26 mice, 3 mice from the PBS group and 4 from the IRT5 group underwent gut microbiome analysis. The average taxonomic composition changed in both groups (Fig. 4A, Supplementary Table S3). The *Firmicutes to Bacteroidetes* ratio was not significantly different between the two groups, and there was also no difference between pre- and posttreatment samples (Fig. 4B). There were no significant differences in the alpha diversity analyzed using the Chao1 index, Shannon index, or phylogenetic diversity index (Fig. 4C). The separation between the IRT5 and PBS groups was observed using a Bray-Curtis principal coordinate analysis (Fig. 4D).
FLurve 4. Gut microbiome changes after the PBS (n = 3) and IRT5 (n = 4) treatment with antibiotic pretreatment. (A) Average taxonomic composition at the family level before and after the PBS and IRT5 treatment. (B) The Firmicutes to Bacteroidetes ratio was not significantly different between the two groups. (C) Alpha diversity analyzed using the Chao1 index, Shannon index, and phylogenetic diversity index. No significant differences were observed between before and after the PBS and IRT5 treatments. (D) Scatterplot showing the first principal coordinate (PC) versus the second PC using Bray-Curtis and UniFrac analysis. Percentages shown are the percentages of variation explained by the components.

LEfSe analysis and Kruskal-Wallis tests were performed to compare the differences in gut microbiota pre- and posttreatment and between the IRT5 and PBS groups. In the IRT5-treated group, the taxonomic relative abundance of 33 different OTUs, including a Lactobacillus helveticus group, Lactobacillus hamsteri, a L. reuteri group, a L. casei group, a Lactobacillus brantae group, a Lactobacillus amylovorus group, Akkermansiamuciniphila, an Aerococcusviridans group, B. bifidum, and a Streptococcus salivarius group, was significantly higher than in the PBS-treated group. In contrast, the relative abundance of 53 OTUs, including an Escherichia coli group, was significantly lower in the IRT5-treated group than in the PBS-treated group (Supplementary Table S4).
IRT5 Probiotics Treatment without Antibiotic Pretreatment Also Improves Autoimmune Dry Eye and Modifies Gut Microbiome Composition

To rule out the effect of antibiotics, we conducted an additional experiment administering IRT5 probiotics or PBS without pretreatment with antibiotics. After IRT5 treatment without the antibiotic pretreatment, the ocular staining scores significantly decreased compared with the pretreatment group \((P = 0.0042, \text{Wilcoxon matched-pairs signed rank test})\) and the PBS treatment group \((P = 0.0011, \text{Mann-Whitney} U \text{test})\). However, tear secretion was not significantly different in the IRT5-treated group when compared with the PBS-treated group \((P = 0.6334, \text{Mann-Whitney} U \text{test})\) or the pretreatment group \((P = 0.5566, \text{Wilcoxon matched-pairs signed rank test})\) (Fig. 5A).

The IL-10 was significantly higher \((P = 0.0343, \text{Mann-Whitney} U \text{test})\) and the IL-1\(\beta\) significantly lower \((P = 0.0434, \text{Mann-Whitney} U \text{test})\) in the conjunctiva and cornea of the IRT5-treated group (Fig. 5B).

The averaged taxonomic composition changed in both groups (Fig. 5C). Neither the Firmicutes to Bacteroidetes ratio nor alpha diversity analyzed using the Chao1 index were not significantly different between the two groups. (E) Compared to the PBS-treated group, Lactobacillus intestinalis was lower, and the Lactobacillus helveticus group, Lactobacillus hamsteri, and the Staphylococcus saprophyticus group were higher in the IRT5-treated group.

IRT5 Treatment Downregulates Antigen Presentation by the Immune Cells

Notably, the IRT5 and PBS treatment showed more differences in the CD11c\(^+\) and CD11b\(^+\) cells of the spleen than in the CD3\(^+\) cells of the lymph node, and the splenic CD11c\(^+\) cells showed the largest difference between the PBS treatment group and the IRT5 treatment group (Supplementary Fig. S1). A total of 574 DEPs were identified in the spleen CD11c\(^+\) cells. Proteins associated with antigen presentation were significantly decreased in the spleen CD11c\(^+\) cells of the IRT5-treated group (Table 4).
Table 3. Differences in Abundance of Bacterial Communities as Assessed by LEfSe

<table>
<thead>
<tr>
<th>Taxon Name</th>
<th>Post PBS</th>
<th>Post IRT</th>
<th>LDA Effect Size</th>
<th>q Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAC001071_s</td>
<td>1.40115</td>
<td>2.54230</td>
<td>3.75640</td>
<td>0.01452</td>
</tr>
<tr>
<td>PAC001112_s</td>
<td>1.14062</td>
<td>2.00330</td>
<td>3.63493</td>
<td>0.01453</td>
</tr>
<tr>
<td>PAC001118_s</td>
<td>0.00739</td>
<td>0.69573</td>
<td>3.53691</td>
<td>0.02864</td>
</tr>
<tr>
<td>Lactobacillus helveticus group</td>
<td>0.00000</td>
<td>0.21799</td>
<td>3.03857</td>
<td>0.01054</td>
</tr>
<tr>
<td>PAC002441_s</td>
<td>0.25844</td>
<td>0.38583</td>
<td>2.80774</td>
<td>0.01466</td>
</tr>
<tr>
<td>PAC001244_s</td>
<td>0.00341</td>
<td>0.12922</td>
<td>2.80012</td>
<td>0.01401</td>
</tr>
<tr>
<td>Decreased</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactobacillus intestinalis</td>
<td>10.72607</td>
<td>4.84257</td>
<td>4.46862</td>
<td>0.02843</td>
</tr>
<tr>
<td>PAC001128_s</td>
<td>0.58433</td>
<td>0.33275</td>
<td>3.10076</td>
<td>0.02849</td>
</tr>
<tr>
<td>PAC001121_s group</td>
<td>0.25399</td>
<td>0.01503</td>
<td>3.07787</td>
<td>0.01400</td>
</tr>
<tr>
<td>PAC001554_s</td>
<td>0.22915</td>
<td>0.08702</td>
<td>2.85228</td>
<td>0.01462</td>
</tr>
<tr>
<td>PAC001560_s</td>
<td>0.14342</td>
<td>0.01524</td>
<td>2.80823</td>
<td>0.01464</td>
</tr>
<tr>
<td>PAC002039_s</td>
<td>0.13548</td>
<td>0.00990</td>
<td>2.79886</td>
<td>0.01404</td>
</tr>
<tr>
<td>PAC002419_s</td>
<td>0.12160</td>
<td>0.05311</td>
<td>2.53967</td>
<td>0.02855</td>
</tr>
<tr>
<td>PAC001586_s</td>
<td>0.09531</td>
<td>0.00502</td>
<td>2.43771</td>
<td>0.02562</td>
</tr>
<tr>
<td>PAC001235_s</td>
<td>0.08000</td>
<td>0.02974</td>
<td>2.41812</td>
<td>0.01456</td>
</tr>
<tr>
<td>PAC002514_s</td>
<td>0.04626</td>
<td>0.00175</td>
<td>2.35018</td>
<td>0.02568</td>
</tr>
<tr>
<td>PAC001588_s</td>
<td>0.05335</td>
<td>0.01130</td>
<td>2.33173</td>
<td>0.02565</td>
</tr>
<tr>
<td>PAC001402_s</td>
<td>0.05175</td>
<td>0.01300</td>
<td>2.29307</td>
<td>0.01458</td>
</tr>
<tr>
<td>PAC001543_s</td>
<td>0.03263</td>
<td>0.00800</td>
<td>2.12408</td>
<td>0.05199</td>
</tr>
<tr>
<td>PAC001536_s</td>
<td>0.02481</td>
<td>0.00000</td>
<td>2.10187</td>
<td>0.03048</td>
</tr>
<tr>
<td>PAC001772_s</td>
<td>0.02204</td>
<td>0.00468</td>
<td>2.07747</td>
<td>0.01403</td>
</tr>
</tbody>
</table>

Table 4. Differentially Expressed Proteins Associated with Antigen Presentation in the Spleen CD11c<sup>+</sup> Cells

<table>
<thead>
<tr>
<th>Protein Name</th>
<th>Gene Name</th>
<th>Fold Changes in CD11c&lt;sup&gt;+&lt;/sup&gt; Cells (IRT5/PBS)</th>
<th>Fold Changes in CD11b&lt;sup&gt;+&lt;/sup&gt; Cells (IRT5/PBS)</th>
<th>P Value</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class II histocompatibility antigen, M beta 1 chain (H2-M beta 1 chain)</td>
<td>H2-DMb1</td>
<td>0.468</td>
<td></td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>H-2 class I histocompatibility antigen, D-37 alpha chain</td>
<td>H2-T23</td>
<td></td>
<td>0.576</td>
<td>0.026</td>
<td></td>
</tr>
<tr>
<td>Immunoglobulin J chain</td>
<td>Jchain</td>
<td>0.488</td>
<td>0.281</td>
<td>0.001</td>
<td>0.006</td>
</tr>
<tr>
<td>Ig alpha chain C region</td>
<td>IGHA1</td>
<td>0.507</td>
<td></td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>Ig gamma-2B chain C region</td>
<td>Igh-3</td>
<td></td>
<td>0.469</td>
<td></td>
<td>0.000</td>
</tr>
</tbody>
</table>

DISCUSSION

The present study indicates that the application of IRT5 probiotics changes the protein expression associated with immunomodulation in the extraorbital lacrimal gland, resulting in the improvement of dry eye signs. This is interesting as it is the first experimental study to report that the proteome of the lacrimal gland can be altered by modulating the gut microbiome.

IL-1β was significantly lower and IL-10 significantly higher in the conjunctiva and cornea of the IRT5-treated group than in those of the PBS-treated group. Similarly, there was a tendency toward an increase of IL-10, an anti-inflammatory cytokine, and decreases of IL-6 and IL-1β in the extraorbital lacrimal glands of the IRT5-treated group, despite the fact that the trend was not significant due to the small sample size (Supplementary Fig. S2). These findings are in line with our previous report that the inflammation foci score of the extraorbital lacrimal gland was significantly lower in the IRT5 group than in the PBS group. Changes in the lacrimal glands can affect the ocular surface, possibly through tears containing anti- and proinflammatory cytokines, growth factors, and other proteins. Although we did not evaluate the tear directly, our results suggest that changes in the lacrimal gland may affect the ocular surface.

In particular, Psmb9, PTPRC, and TAP2, which are known to be upregulated in Sjögren syndrome, were downregulated in IRT5-treated mice. Psmb8 and Psmb9 activate NF-κB in B cells and process the numerous MHC class I restricted T-cell epitopes. PTPRC modulates signaling mediated by the T-cell receptor and activates B-cell antigen receptor signaling, which modulates susceptibility to autoimmune diseases. TAP2 is involved in the
IRT5 Changes the Lacrimal Gland Protein Expression

Investigative Ophthalmology & Visual Science

transportation of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I epitopes, and TAP2 polymorphism has been associated with ankylosing spondylitis. Psmb8 and PTPRC also showed strong centralities within immune system process and could be regarded as key molecules in the anti-inflammatory role of IRT5 treatment. This finding corresponds well with the results of a previous meta-analysis showing these proteins to be key contributors to Sjögren syndrome in humans. Therefore, we reasoned that IRT5 treatment ameliorates dry eye by reducing the level of these proteins and their related biological processes. Although its association with Sjögren syndrome is not clear, the expression of intracellular adhesion molecule 1 was also attenuated. HMGB2, as a probable factor causing or aggravating Sjögren syndrome, showed moderate centrality between leukocyte-cell adhesion and the phagocytosis network, and its expression decreased with IRT5 treatment. Cox7c, which was downregulated, regulates electron transfer and decreases the mitochondrial H+ gradient. Therefore, Cox7c downregulation may reduce adenosine triphosphate (ATP) production and decrease activation of P2 purinergic receptors, which may contribute to inflammatory processes.

Among the upregulated DEPs was Chmp4c, one of the components of transport complex III. Chmp4c sorts endosomal cargo proteins into multivesicular bodies (MVBs) and is involved in MVB formation. Chmp4c showed a higher rate of expression when treated with IRT5, which may result in the formation of MVBs that may, in turn, affect degradation processes. Pex6, a member of the AAA (ATPases associated with diverse cellular activities) family of ATPases, also helps with protein import into peroxisomes. Peroxisomes have two functions, diverse reactions in the lipid metabolism and defense systems for scavenging peroxides and reactive oxygen species. Upregulation of Pex6 may reduce oxidative stress by promoting the import of peroxisomal protein.

In addition, Ube2d3, encoding a member of the E2 ligase family, was downregulated, although genes encoding the other DEPs associated with proteolysis and degradation were upregulated after IRT5 treatment. The connection between proteolysis and dry eye is not clear. Given that the ubiquitin proteasome pathway is responsible for generating the precise C termini of MHC-presented peptides, proteolytic changes may be associated with immune response.

Gut dysbiosis plays an important role in autoimmune disease. Sjögren syndrome also shows reduced diversity in the gut microbiota. A recent clinical study reported that administration of Bifidobacterium may attenuate dry eye syndrome. In agreement with this observation, our previous and current preclinical studies both showed that changes in the gut microbiome after IRT5 treatment were associated with improvements in the clinical signs of autoimmune dry eye disease.

Interestingly, the L. helveticus group and L. hamsteri were higher in the IRT5 group than in the PBS group, regardless of antibiotic pretreatment. The R0052 strain of L. helveticus is a component of Lacidophil (Rossell Institute, Montreal, Canada) and has been used as a probiotic since 1995. It has been reported that it inhibits the adhesion of bacteria and modulates immune function by downregulating proinflammatory cytokines. Additionally, the N88 strain of L. helveticus has also been reported to exhibit immunomodulatory properties by inducing higher levels of IL-10. Although no clinical studies have reported that Lactobacillus intake increases IL-10 expression on the ocular surface, an increase of serum IL-10 with an immunosuppressive effect was shown after Lactobacillus intake in atopic dermatitis. Consistent with previous reports, IL-10 on the ocular surface was increased in the IRT5-treated group, suggesting that the immunomodulatory effect might be related to L. helveticus. Therefore, we believe that probiotics may alter the gut microbiome to show systemic anti-inflammatory effects that could reach the ocular mucosal surface as well as other targets of autoimmune disease.

However, not many studies on L. hamsteri have been published. Therefore, the immunomodulating function of L. hamsteri needs to be further evaluated. Interestingly, three (the L. reuteri group, the L. casei group, and B. bifidum) of the five strains constituting IRT5 were increased in the IRT5-treated group compared with the PBS-treated group only when antibiotic pretreatment was provided. Correspondingly, tear secretion increased in the IRT5-treated group only when antibiotic pretreatment was performed. These results suggest that pretreatment with antibiotics promotes IRT5 establishment and maximizes the therapeutic effects without severely diminishing microbial diversity. Suez et al. also reported that antibiotic treatment partially alleviated resistance to probiotic species and mildly enhanced probiotic colonization.

However, there is controversy about pretreatment with antibiotics before taking probiotics. Manichanh et al. reported a twofold decrease in microbial load after administration of imipenem and vancomycin for 3 days. They also reported a significant decrease of Bacteroidetes and an increase of Firmicutes. Although not statistically significant, the Firmicutes to Bacteroidetes ratio in our study increased more than 10-fold in both the PBS- and IRT5-treated groups after antibiotic pretreatment, while the ratio remained the same without the antibiotic pretreatment. In addition, antibiotic intake changed the taxonomic composition but did not reduce microbial diversity. Previous studies have reported a wide range of losses of alpha diversity after antibiotic exposure, ranging from 10% to 80%. This might be due to differences in the type of antibiotics used or the vulnerability of the host. Since it is known that changes in the gut microbiome caused by antibiotics increase the risk of diabetes and allergies, further research on the immune system changes caused by antibiotics should be conducted.

It is well known that the gut microbiome is involved in the host immune system, but the mechanism is unclear. We could not directly correlate proteomic changes in the lacrimal gland with compositional changes in the gut microbiome. Given the previous report that probiotics cause a large change in intestinal transcription without significantly changing the composition of the microbiome, it can be inferred that the changes in the microbiome after IRT5 administration influenced the lacrimal protein changes in this study. Using an additional mechanistic study, we revealed that the CD11c+ cells of the spleen showed larger proteomic changes than the CD3+ cells of the lymph nodes. We found that the proteins related to the antigen presentation pathway were significantly decreased in the IRT5-treated group. This is consistent with previous reports that the gut microbiome affects intestinal dendritic cell functioning and impacts immune homeostasis. To support these findings, we retrospectively reanalyzed flow cytometry data from the previous experiments. The proportion of MHCII+ cells in the cervical lymph node was also lower in the IRT5-treated group (n = 10, 24.01 ± 3.69) than in the PBS-treated group (n = 10, 28.58 ± 2.22) (P = 0.0052, Mann-Whitney U test).
FIGURE 6. Changes in the gut microbiome after IRT5 administration is suggested to contribute to the immune modulation of the eye via the downregulation of the antigen presentation process in the spleen. Changes in metabolites caused by the gut microbiome and transmitted to the eye through the bloodstream can also be hypothesized as a plausible mechanism.

$U$ test (Supplementary Fig. S3). From these results, it can be deduced that the downregulation of antigen presentation is one of the mechanisms of the immunomodulation caused by the administration of IRT5 (Fig. 6). Another speculation is that short-chain fatty acid or tryptophan derivatives, which are known to affect neuroinflammation in the central nervous system, may also contribute to the immune modulation of the eye. Further studies are warranted to identify the metabolites that affect the microbiome-gut-eye axis.

Our study has some limitations. First, the analysis method, which targeted the V3 to V4 regions of the 16S rRNA gene, could not identify the exact strain of the microbiome. As it is known that actions can vary depending on the type of strain even within one species, whole-genome sequencing is needed. Similarly, the current study is based on OTUs with a cutoff value of 97%. Even if the organisms share more than 97% of the entire 16S rRNA gene sequence, they may or may not represent the same species. Second, the number of animals used in the experiment was small due to difficulties in breeding them. Third, even if mice are bred under the same food and environmental conditions, there are already microbiome variations between the mice before the experiment. Only male NOD.B10.H2b mice were used in this experiment because females tend to develop sialadenitis instead of dacryoadenitis. This sex restriction limited co-housing before the experiments because males fight to the death when co-housed. Additional pretreatment, such as fecal microbiota transplantation, should be considered in further experiments. Fourth, we could not invasively obtain samples directly from the gut but instead collected noninvasive fecal samples. Given that the microbiome composition is different in each part of the intestinal tract, the taxonomic composition measured in the feces can be different. Therefore, using the fecal microbiome alone is limited in determining the effects of IRT5 on the whole microbiome of the host.

In this study, we investigated changes in the gut microbial community and the proteome of the lacrimal gland after IRT5 treatment in an animal model of Sjögren syndrome. Our findings can be summarized as follows. First, ocular inflammation and tear secretion improved after IRT5 treatment. Second, proteins in defense response and immune system process were downregulated in the extraorbital lacrimal gland after IRT5 treatment. Third, IRT5 treatment induced changes in the composition of several OTUs, including the *L. helveticus* group and *L. hamsteri*. Our observations may be beneficial in understanding the pathophysiology of the gut-microbiota-eye axis in dry eye disease.

**Acknowledgments**

The authors thank Editage (www.editage.co.kr) for English language editing. IRT-5 probiotics were kindly provided by Young-Tae Ahn (Korea Yakult Co., Giheung, Korea).

Supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No.2017R1A2B2007209).
References


IRT5 Changes the Lacrimal Gland Protein Expression


